Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients

AKAR S., Cetin P., KALYONCU U., KARADAĞ Ö., SARI İ., Cinar M., ...More

ARTHRITIS CARE & RESEARCH, vol.70, no.7, pp.1090-1094, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1002/acr.23446
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1090-1094
  • Dokuz Eylül University Affiliated: Yes


ObjectiveApproximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients.